Regular Hours
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| Valuation Estimation |
|
EPS (Current/Estimated)
-3.56/-1.90
|
|
Enterprise Value
39.89M
|
| Balance Sheet |
|
Book Value Per Share
-1.23
|
| Cash Flow |
|
Cash Flow Yield
--
|
| Income Statement |
|
Total Revenue
1.34M
|
|
Operating Revenue Per Share
0.03
|
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Quotes are at least 15-min delayed:2025/11/19 11:06 EST
Industry overview quotes are at least 15 minutes delayed
|
Business Description
|
|||
| Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat. |

3.5129 
